Form 8-K PROVECTUS BIOPHARMACEUTI For: Aug 09
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Provectus Biopharma (PVCT) Reports Q2 Loss of $0.02/Share
August 11, 2016 9:29 AM EDTProvectus Biopharma (NYSE: PVCT) reported Q2 EPS of ($0.02), versus ($0.02) reported last year.
Our cash and cash equivalents were $4,891,313 at June 30, 2016, compared with $9,760,997 at March 31, 2016.
For earnings history and earnings-related data on Provectus Biopharma (PVCT) click here.
... More